Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF
Abstract Purpose Can relugolix, a novel oral gonadotropin‐releasing hormone receptor (GnRH) antagonist, function as an alternative ovulation inhibitor to GnRH antagonist injections? Methods This single‐center, cross‐sectional retrospective study compared premature ovulation rates and clinical outcom...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Reproductive Medicine and Biology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rmb2.12422 |
| _version_ | 1797975986485067776 |
|---|---|
| author | Kazuki Nakao Keiji Kuroda Takashi Horikawa Azusa Moriyama Hiroyasu Juen Akiko Itakura Hideaki Watanabe Satoru Takamizawa Yuko Ojiro Koji Nakagawa Rikikazu Sugiyama |
| author_facet | Kazuki Nakao Keiji Kuroda Takashi Horikawa Azusa Moriyama Hiroyasu Juen Akiko Itakura Hideaki Watanabe Satoru Takamizawa Yuko Ojiro Koji Nakagawa Rikikazu Sugiyama |
| author_sort | Kazuki Nakao |
| collection | DOAJ |
| description | Abstract Purpose Can relugolix, a novel oral gonadotropin‐releasing hormone receptor (GnRH) antagonist, function as an alternative ovulation inhibitor to GnRH antagonist injections? Methods This single‐center, cross‐sectional retrospective study compared premature ovulation rates and clinical outcomes in IVF treatment after mild ovarian stimulation with 40 mg of relugolix (relugolix group) or 0.25‐mg injections of ganirelix acetate or cetrorelix acetate (injection group) between March 2019 and January 2020. Of 247 infertile women (256 IVF cycles) aged ≤42 years, 223 women (230 cycles) were evaluated. In the relugolix and injection groups, we compared 104 and 85 cycles after GnRH antagonist use before the LH surge (LH levels <10 mIU/ml) and 22 and 19 cycles during the LH surge (LH levels ≥10 mIU/ml), respectively. Results Before the LH surge, the ovulation rates in the two groups were very low (p = 0.838), however; during the LH surge, the cycles using relugolix had a high ovulation rate of 40.9% compared with no ovulation in the injection group (p = 0.002). There were no significant differences in embryo culture findings and pregnancy outcomes between the two groups. Conclusions Although relugolix had a high ovulation suppressive effect, when the LH surge occurred, its effect was insufficient. |
| first_indexed | 2024-04-11T04:44:07Z |
| format | Article |
| id | doaj.art-14d5264e29b64583be2087a3a0c94488 |
| institution | Directory Open Access Journal |
| issn | 1445-5781 1447-0578 |
| language | English |
| last_indexed | 2024-04-11T04:44:07Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Reproductive Medicine and Biology |
| spelling | doaj.art-14d5264e29b64583be2087a3a0c944882022-12-27T13:54:58ZengWileyReproductive Medicine and Biology1445-57811447-05782022-01-01211n/an/a10.1002/rmb2.12422Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVFKazuki Nakao0Keiji Kuroda1Takashi Horikawa2Azusa Moriyama3Hiroyasu Juen4Akiko Itakura5Hideaki Watanabe6Satoru Takamizawa7Yuko Ojiro8Koji Nakagawa9Rikikazu Sugiyama10Center for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanCenter for Reproductive Medicine and Implantation Research Sugiyama Clinic Shinjuku Tokyo JapanAbstract Purpose Can relugolix, a novel oral gonadotropin‐releasing hormone receptor (GnRH) antagonist, function as an alternative ovulation inhibitor to GnRH antagonist injections? Methods This single‐center, cross‐sectional retrospective study compared premature ovulation rates and clinical outcomes in IVF treatment after mild ovarian stimulation with 40 mg of relugolix (relugolix group) or 0.25‐mg injections of ganirelix acetate or cetrorelix acetate (injection group) between March 2019 and January 2020. Of 247 infertile women (256 IVF cycles) aged ≤42 years, 223 women (230 cycles) were evaluated. In the relugolix and injection groups, we compared 104 and 85 cycles after GnRH antagonist use before the LH surge (LH levels <10 mIU/ml) and 22 and 19 cycles during the LH surge (LH levels ≥10 mIU/ml), respectively. Results Before the LH surge, the ovulation rates in the two groups were very low (p = 0.838), however; during the LH surge, the cycles using relugolix had a high ovulation rate of 40.9% compared with no ovulation in the injection group (p = 0.002). There were no significant differences in embryo culture findings and pregnancy outcomes between the two groups. Conclusions Although relugolix had a high ovulation suppressive effect, when the LH surge occurred, its effect was insufficient.https://doi.org/10.1002/rmb2.12422Gonadotropin‐releasing hormone receptor antagonistin vitro fertilizationmild ovarian stimulationpremature ovulationrelugolix |
| spellingShingle | Kazuki Nakao Keiji Kuroda Takashi Horikawa Azusa Moriyama Hiroyasu Juen Akiko Itakura Hideaki Watanabe Satoru Takamizawa Yuko Ojiro Koji Nakagawa Rikikazu Sugiyama Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF Reproductive Medicine and Biology Gonadotropin‐releasing hormone receptor antagonist in vitro fertilization mild ovarian stimulation premature ovulation relugolix |
| title | Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF |
| title_full | Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF |
| title_fullStr | Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF |
| title_full_unstemmed | Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF |
| title_short | Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF |
| title_sort | therapeutic effects of an oral gonadotropin releasing hormone receptor antagonist relugolix on preventing premature ovulation in mild ovarian stimulation for ivf |
| topic | Gonadotropin‐releasing hormone receptor antagonist in vitro fertilization mild ovarian stimulation premature ovulation relugolix |
| url | https://doi.org/10.1002/rmb2.12422 |
| work_keys_str_mv | AT kazukinakao therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT keijikuroda therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT takashihorikawa therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT azusamoriyama therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT hiroyasujuen therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT akikoitakura therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT hideakiwatanabe therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT satorutakamizawa therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT yukoojiro therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT kojinakagawa therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf AT rikikazusugiyama therapeuticeffectsofanoralgonadotropinreleasinghormonereceptorantagonistrelugolixonpreventingprematureovulationinmildovarianstimulationforivf |